Eli Lilly and (LLY)

NYSE: LLY · Real-Time Price · USD

899.34

14.14 (1.60%)

At close: Apr 30, 2025, 3:59 PM

856.10

-4.81%

Pre-market: May 01, 2025, 08:00 AM EDT

1.60% (1D)

Bid	856
Market Cap	852.56B
Revenue (ttm)	45.04B
Net Income (ttm)	10.59B
EPS (ttm)	11.68
PE Ratio (ttm)	77
Forward PE	30.4
Analyst	Buy

Ask	860
Volume	3,060,513
Avg. Volume (20D)	3,689,068
Open	888.20
Previous Close	885.20
Day's Range	882.12 - 902.50
52-Week Range	677.09 - 972.53
Beta	0.50

About LLY

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer ...

[Read more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date Jun 1, 1972

Employees 47,000

Stock Exchange NYSE

Ticker Symbol LLY

Website https://www.lilly.com

Full Company Profile

Analyst Forecast

According to 25 analyst ratings, the average rating for LLY stock is "Buy." The 12-month stock price forecast is $1000.5, which is an increase of 11.25% from the latest price.

Stock Forecasts

Earnings Surprise

New

Eli Lilly and has released their quartely earnings on May 1, 2025:

Revenue of $12.73B exceeds estimates by $69M, with 45.18% YoY growth.

EPS of 3.34 exceeds estimates by 0.32, with 29.46% YoY growth.

Next Earnings Release

Eli Lilly and is scheduled to release its earnings on May 1, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

Just now New

Eli Lilly shares are trading lower after the compa... Unlock content with Pro Subscription

2 days ago

-0.82%

Eli Lilly shares are trading lower after HSBC downgraded the stock from Buy to Reduce and lowered the price target from $1,150 to $700.

News

Just now · benzinga.com

Eli Lilly Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Eli Lilly and Company LLY will release earnings results for the first quarter, before the opening bell on Thursday, May 1.

21 hours ago · benzinga.com

Eli Lilly Stock Has The Technicals: Will Q1 Earnings Deliver Fundamentals?

Eli Lilly And Co LLY will be reporting its first-quarter earnings on Thursday. Wall Street expects $3.05 in EPS and $12.67 billion in revenues as the company reports before market hours.

18 hours ago · fool.com

Eli Lilly's Stock Is Up 15% This Year, and Here's Why It Could Take Off Even More

Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly (LLY 1.09%). It is the most valuable healthcare company in the world, with a market cap ...

1 day ago · https://247wallst.com

S&P 500 (VOO) Live: Trump Administration Blasts Amazon.com, and the S&P 500 Tumbles

Live Updates Live Coverage Has Ended S&P 500 Extends Its Winning Streak 4:18 pm The S&P 500 closed up 0.6% for Tuesday, extending its winning streak to six straight days. Trade Talks Keep S&am...

2 days ago · seekingalpha.com

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...

1 day ago · businesswire.com

Creyon Bio and Lilly Enter into RNA-Targeted Oligo Therapy Development Collaboration

SAN DIEGO--(BUSINESS WIRE)-- #AIinHealthcare--Creyon Bio, Inc. (“Creyon”) today announced a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) focused on the...

2 days ago · seekingalpha.com

Eli Lilly: Why Orforglipron Matters, A Lot

Eli Lilly and Company's orforglipron generated positive results in the phase 3 trial in type 2 diabetes patients. The results look good or better than oral semaglutide (across trials) and similar to i...

2 days ago · youtube.com

Calls of the Day: Eli Lilly

Which stock rocked the table with a double downgrade? The Investment Committee reveals today's Calls of the Day!

2 days ago · zacks.com

Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?

Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.

2 days ago · barrons.com

Eli Lilly Stock Just Got Its First Bear. Where Weight-Loss Drugs Go From Here.

HSBC double downgraded Eli Lilly to Reduce, citing too much optimism around its new weight-loss pill, and the strength of Novo Nordisk's Ozempic brand.

Load More News